Charles River Laboratories International, Inc.

NYSE:CRL

Medical - Diagnostics & Research

Healthcare
$333.25 -1.33%

-$2.45 today

Market cap
$15.97B
Beta
1.45
P/E (TTM)
-48.3
EPS (TTM)
-$3.77
52W Low $144.26High $228.88

Volume 0.52M

Average 0.86M

CRL Pre-Tax Margin

Income before tax as a percentage of revenue.

Charles River Laboratories International, Inc.NYSE: CRL

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to 5.3%

Pre-tax margin was 5.3% in Q2 FY2026, down 1.6 pp from a year earlier. On a trailing-twelve-month basis it was -4.6%, down 4.1 pp year over year. Over 3 fiscal years it narrowed by 18.1 pp.

Context

  • Pre-tax margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
5.3%+8.3 pp QoQ
Last fiscal yearDec 2025
-2.5%-4.8 pp YoY
LTMJun 2026
-4.6%-4.1 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.6 pp——
1 year-4.8 pp——
3 years-18.1 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2.5%
Year-over-year change
-4.8pp

Pre-Tax Margin vs competitors

How CRL compares with its peers on the latest reported figures

  • CRL's LTM Jun 2026 pre-tax margin of -4.6% is the lowest of the 4 companies compared; the peer median is 5.1%.
  • Its year-over-year change of -4.1 pp is the 3rd highest of 4, against a peer median of +0.1 pp.
  • Over three fiscal years its change of -18.1 pp compares with a peer median of -3.8 pp.
CRL Competitors Peer median
Pre-Tax Margin for CRL and competitors
Company Period LTM level YoY 3-year change
MEDPMedpace Holdings, Inc.LTM Sep 202622.1% +0.1 pp+2.1 pp
ICLRICON Public Limited CompanyLTM Jun 20265.1% -5.1 pp-4.2 pp
CERTCertara, Inc.LTM Mar 2026-1.2% +0.7 pp-3.8 pp
CRLCharles River Laboratories International, Inc.LTM Jun 2026-4.6% -4.1 pp-18.1 pp
Peer median (excluding CRL) 5.1%+0.1 pp-3.8 pp

Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.54B3.98B4.13B4.05B4.02B
Cost of Revenue2.21B2.51B2.63B2.72B2.79B
Gross Profit1.33B1.46B1.5B1.33B1.23B
Gross Margin37.7%36.8%36.4%32.9%30.5%
Research & Development00000
Selling, General & Admin619.92M665.1M747.86M751M743.07M
Operating Expenses744.78M811.68M885.3M1.1B717.73M
Depreciation & Amortization265.54M303.87M314.12M361.74M403.31M
EBITDA820.16M986.15M1.03B581.14M410.84M
EBITDA Margin23.2%24.8%25.0%14.3%10.2%
Operating Income589.86M650.98M617.26M227.35M507.84M
Operating Margin16.7%16.4%14.9%5.6%12.6%
Interest Income652K780K5.2M8.58M4.94M
Interest Expense73.91M59.29M136.71M126.29M107.03M
Other Income / Expenses(109.15M)(27.99M)(35.98M)(134.23M)(607.34M)
Income Before Tax480.71M622.99M581.28M93.11M(99.5M)
Pre-Tax Margin13.6%15.7%14.1%2.3%-2.5%
Income Tax Expense81.87M130.38M100.91M67.82M42.66M
Net Income390.98M486.23M474.62M10.3M(144.34M)
Net Margin11.0%12.2%11.5%0.3%-3.6%
EPS (Basic)7.779.579.270.20(2.91)
EPS (Diluted)7.609.489.220.20(2.91)
Weighted Avg Shares50.29M50.81M51.23M51.38M49.56M
Weighted Avg Shares (Diluted)51.43M51.3M51.45M51.63M49.56M

Charles River Laboratories International, Inc.

NYSE:CRL

Intrinsic Alpha fair value

Locked

Current Price

$333.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.